{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 39,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "Includes statistical significance markers and clinical guideline thresholds.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/19",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.66,
        "x": 0.17,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Primary Endpoint Met – 24 Week Analysis: 76.7% reduction from baseline in mean plasma arginine with pegzilarginase treatment compared to placebo (p<0.0001)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c99546c-9e65-449c-b3a4-28a4ab5a8801",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Proportion of Patients Reaching Normal Arginine Levels",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a845cd9-b4d9-410d-9e7f-34ae0ec90443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Primary Endpoint: Reduction in Plasma Arginine",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e049263f-71f0-4b27-8d69-1c99c0af7578",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.21,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Enns G, et al. Poster presented at SIMD 2022 Annual Meeting; *Based on arithmetic mean of values from visit and preceding 3 visits, boxes represent middle 50% with error bars depicting 95% confidence interval; ‡ Statistical analysis based on geometric mean; †Nominal p value, based on arithmetic mean of values from visit and preceding 3 visits",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f9c9549-02fc-41df-9ac0-2a8a68e7fe0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "PEACE Phase 3 Trial: Marked and Sustained Reduction in Plasma Arginine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83034ecf-004f-4467-a08d-4a6f3b98c9a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}